ArticleFrontiers in pharmacology2024
Pharmacogenetics testing for poor response to antidepressants: a transnosographic case series.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers and facilitators to the implementation of pharmacogenomic testing for antidepressants use in primary care: a systematic review using the consolidated framework for implementation research.The pharmacogenomics journal · 2026Pooled it
- Pharmacogenomic-Guided Prescribing for Treatment-Resistant Mental Health Conditions in Australian Primary Care: A Single-GP Practice Retrospective Observation of 29 Patients.International journal of molecular sciences · 2026Article
- The clinical value of pharmacogenomics in the pharmacotherapy of common psychiatric disorders: a macroscopic analysis based on real-world data.BMC psychiatry · 2026Article
- Integrating CRISPR functional genomics with admixture-aware psychotropic pharmacogenetics in Brazil.Frontiers in pharmacology · 2026Review
- Association between the combination of GABAergic agents and SSRIs at the first clinical visit and depressive symptom trajectories: A study using group-based trajectory modeling and Apriori algorithm.PLOS mental health · 2026Article
- Genetic variability and response to sertraline in pediatric populations: a review on pharmacogenetics, pharmacokinetics, and the risk of adverse events.Frontiers in child and adolescent psychiatry · 2026Review
- Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pharmacogenetics (PGx) holds promise for optimizing psychotropic medication use, with Methods: This case series includes 40 patients who underwent PGx testing due to antidepressant ineffectiveness or ADRs between June 2020 and April 2022. We describe the patients' demographic, clinical, and genetic characteristics and assess the value of PGx testing based on feedback from their psychiatrists. Results: The most common diagnoses were major depressive disorder (60.0%) and post-traumatic stress disorder (30.0%). Ineffectiveness was reported in 65.0% of patients, ADRs in 2.5%, and both in 32.5%. The antidepressants involved included SSRIs (45.0%), SNRIs (27.5%), atypical antidepressants (20.0%), and tricyclics (17.5%). Only 17.5% of patients had normal Discussion: Our findings suggest that PGx testing can guide prescribing decisions for patients with antidepressant ineffectiveness or ADRs. The relatively high prevalence of genetic variants affecting pharmacokinetics supports the broader adoption of PGx testing in psychiatric practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.